普卢格列汀片;;
1.Deng,W.,Zhao,L.,Chen,C.,Ren,Z.,Jing,Y.,Qiu,J.,Liu,D.（2024）.NationalburdenandriskfactorsofdiabetesmellitusinChinafrom1990to2021:ResultsfromtheGlobalBurdenofDiseasestudy2021.JournalofDiabetes,16（10）,e70012.
2.《中国老年2型糖尿病防治临床指南（2022年版）》
3.Gregg,EdwardWetal.“Theburdenofdiabetes-associatedmultiplelong-termconditionsonyearsoflifespentandlost.”Naturemedicinevol.30,10(2024):2830-2837.doi:10.1038/s41591-024-03123-2
4.RemelliF,CeresiniMG,TrevisanC,NoaleM,VolpatoS.Prevalenceandimpactofpolypharmacyinolderpatientswithtype2diabetes.AgingClinExpRes.2022Sep;34(9):1969-1983.
5.YunJS,KimK,AhnYB,HanK,KoSH.HolisticandPersonalizedStrategiesforManaginginElderlyType2DiabetesPatients.DiabetesMetabJ.2024;48(4):531-545.
6.AlkabbaniW,MaxwellCJ,MarrieRA,TyasSL,LegaIC,GambleJM.AssociationsofMid-andLate-LifeSevereHypoglycemicEpisodesWithIncidentDementiaAmongPatientsWithType2Diabetes:APopulation-BasedCohortStudy.DiabetesCare.2023Feb1;46(2):331-340;;
1普卢格列汀单药临床三期试验；2.普卢格列汀片说明书；3.苯甲酸阿格列汀片说明书；4.磷酸瑞格列汀片说明书；;;
*：以上数据均来源于各产品说明书，为非头对头数据，仅供参考；HbA1c降低情况为去除安慰剂效应数据;
*：以上数据均来源于各产品说明书，为非头对头数据，仅供参考；HbA1c降低情况为去除安慰剂效应数据;
1.ArakiA.Individualizedtreatmentofdiabetesmellitusinolderadults.GeriatrGerontolInt.2024;24(12):1257-1268
2.XueM,XuW,OuYNetal.Diabetesmellitusandrisksofcognitiveimpairmentanddementia:asystematicreviewandmeta-analysisof144prospectivestudies.AgeingResRev2019.55:100944.
3.Hangaard,S.,Jensen,M.H.EffectofNewerLong-ActingInsulinsonHypoglycemiaandFractureRiskAmongPeoplewithDiabetes:ASystematicReview.CurrOsteoporosRep2021,19,637–643.
4.HsuPF,etal.DiabetesCare.2013;36(4):894900.;
福格列汀;
?糖尿病是我国常见的慢性疾病之一，患病率高达11.2%，且呈逐年上升趋势，我国约有7813万老年人患有糖尿病，纳入本品可为广大患者提供更多治疗选择
?存量替代阿格列汀，对医保基金影响有限；有望降低共病治疗风险从而节省??关医疗费用支出；通过国谈降价纳入目录，可进一步提升可及性及可负担性